Imagion Biosystems has today released its Appendix 4C Quarterly Cash Flow Report and update on Company activities for the quarter ending 31 December 2019.
Read the notice.
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it
1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
